Last reviewed · How we verify
Folliculinum 30C
Folliculinum 30C is a Small molecule drug developed by Shaare Zedek Medical Center. It is currently in Phase 3 development for Infertility and reproductive disorders (homeopathic indication). Also known as: Active Folliculinum.
Folliculinum 30C is a homeopathic preparation derived from follicle-stimulating hormone (FSH) intended to modulate hormonal balance, particularly in reproductive and endocrine contexts.
Folliculinum 30C is a homeopathic preparation derived from follicle-stimulating hormone (FSH) intended to modulate hormonal balance, particularly in reproductive and endocrine contexts. Used for Infertility and reproductive disorders (homeopathic indication).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Folliculinum 30C |
|---|---|
| Also known as | Active Folliculinum |
| Sponsor | Shaare Zedek Medical Center |
| Modality | Small molecule |
| Therapeutic area | Reproductive Health / Endocrinology (homeopathic) |
| Phase | Phase 3 |
Mechanism of action
In homeopathic theory, Folliculinum 30C is a highly diluted preparation of FSH that is believed to stimulate or regulate the body's own FSH production and reproductive function. The 30C potency indicates extreme dilution (10^-60), which is beyond the Avogadro limit and contains no detectable molecular FSH. Homeopathic mechanisms are not supported by conventional pharmacology and remain unproven in rigorous clinical trials.
Approved indications
- Infertility and reproductive disorders (homeopathic indication)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Folliculinum 30C CI brief — competitive landscape report
- Folliculinum 30C updates RSS · CI watch RSS
- Shaare Zedek Medical Center portfolio CI
Frequently asked questions about Folliculinum 30C
What is Folliculinum 30C?
How does Folliculinum 30C work?
What is Folliculinum 30C used for?
Who makes Folliculinum 30C?
Is Folliculinum 30C also known as anything else?
What development phase is Folliculinum 30C in?
Related
- Manufacturer: Shaare Zedek Medical Center — full pipeline
- Therapeutic area: All drugs in Reproductive Health / Endocrinology (homeopathic)
- Indication: Drugs for Infertility and reproductive disorders (homeopathic indication)
- Also known as: Active Folliculinum
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing